![Jared Kelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 95 574 $ al 31/08/2026
Jared Kelly is currently Chief Executive Officer & Director at Oncolytics Biotech, Inc. since 2025.
Mr. Kelly is also Secretary, Senior Vice President & General Counsel at Ambrx Biopharma Cayman, Inc. since 2023.
Formerly, Mr. Kelly was a Partner at Lowenstein Sandler LLP.
Mr. Kelly completed graduate studies at Georgetown University Law Center.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ONCOLYTICS BIOTECH INC. 0,09 % | 01/06/2026 | 114.050 ( 0,09 % ) | 95 574 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Director Ejecutivo | 11/06/2025 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Consejero General | 13/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Lowenstein Sandler LLP
 Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Oncolytics Biotech, Inc.
 Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Georgetown University Law Center
 Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
